Sign in

    Greg Rirenza

    Director and Senior Biotechnology Research Analyst at RBC Capital Markets

    Gregory Renza, M.D., is a Director and Senior Biotechnology Research Analyst at RBC Capital Markets, specializing in coverage of major biotechnology companies including BeiGene and focusing on sectors such as healthcare and biopharma. Renza has delivered strong performance, with a documented 100% success rate and an average return of 37.51% on recommendations, ranking in the top-half of Wall Street analysts. He joined RBC Capital Markets in 2017 after previous roles at Jefferies, Wells Fargo Securities, Booz & Company, and CVS Caremark, and is credentialed with an A.B. in Biology and M.D. from Brown University. His analytical excellence is evident through consistent involvement in industry forums and authoring impactful research for institutional investors.

    Greg Rirenza's questions to ACADIA PHARMACEUTICALS (ACAD) leadership

    Greg Rirenza's questions to ACADIA PHARMACEUTICALS (ACAD) leadership • Q1 2025

    Question

    An analyst on behalf of Greg Rirenza of RBC Capital Markets asked how Acadia's commercial capabilities would provide a competitive edge in the Prader-Willi syndrome market and inquired about the company's supply chain exposure to potential tariffs.

    Answer

    CEO Catherine Owen Adams and CCO Thomas Garner highlighted their experienced rare disease commercial team and key learnings from the DAYBUE launch as significant advantages for competing in the PWS market. CFO Mark Schneyer addressed supply chain concerns by stating that while API is sourced ex-U.S., the company has secured substantial U.S.-based inventory—enough to last into the mid-2030s for NUPLAZID and for several years for DAYBUE—mitigating near-term tariff risks.

    Ask Fintool Equity Research AI